cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo. by Toi, M. et al.
Br. J. Cancer (1993), 68, 1088 1096
Press Ltd., 1993
cDNA transfection followed by the isolation of a MCF-7 breast cell line
resistant to tamoxifen in vitro and in vivo
M. Toil, A.L. Harris & R. Bicknell
Molecular Oncology Laboratory, Imperial Cancer Research Fund, Institute ofMolecular Medicine, University ofOxford, John
Radcliffe Hospital, Oxford OX3 9DU, UK.
Summary A tamoxifen resistant cell line (clone 9) has been isolated from the tamoxifen sensitive, hormone
responsive MCF-7 breast carcinoma cell line after transfection with mixed cDNA libraries, followed by
tamoxifen selection in the presence of oestrogens. Transfection was confirmed by Southern analysis with vector
probes. Clone 9 in several-fold more resistant to tamoxifen and other anti-oestrogens than wild type cells when
cultured either as a monolayer or as colonies in soft agar but retains oestrogen receptors. Clone 9 was less
responsive to 17-p-oestradiol than were wild type MCF-7. In addition to showing in vitro tamoxifen resistance,
clone 9 was also tamoxifen resistant in vivo when xenografted into the nude mouse. Culture medium
conditioned by clone 9 cells stimulated quiescent cells of the same clone as well as wild type cells, whereas
medium conditioned by wild type MCF-7 was inhibitory to both, suggesting that clone 9 may be secreting an
autocrine growth factor. Clone 9 provides a novel model for further investigation of the mechanism of
anti-oestrogen resistance that occurs without loss of oestrogen receptors. Preliminary results suggest that an
autocrine growth stimulatory mechanism may be one pathway of such resistance.
Anti-hormonal therapy has proven a successful strategy in
the treatment of breast cancer and its use in early disease
prolongs survival. Thus, following surgery the anti-oestrogen
tamoxifen is effective in extending both disease free and
overall survival of primary breast cancer patients. Tamoxifen
also induces tumour suppression in about 50% of the
patients with advanced oestrogen receptor positive breast
cancer (Collins et al., 1992; Manni, 1989). A major drawback
in the successful use of anti-oestrogen therapy has been the
development of resistance to the drug. Nearly all patients
with recurrent disease develop resistance after an initial
response and in the case of adjuvant therapy, 40-50% of
node positive cases still relapse and die. Some tamoxifen
resistant tumours respond to a second line hormone manipu-
lation (Harris et al., 1983, 1989). In this case approximately
half of the previous responders respond a second time (Smith
et al., 1983). In contrast, a second resistant subtype is unre-
sponsive to all hormone manipulations despite continued
expression of oestrogen receptors. The mechanisms of the
latter resistance may include over expression of growth fac-
tors (Johnston et al., 1992; Cullen et al., 1992) or growth
factor receptors (Nicholson et al., 1988, 1989; Wright et al.,
1992), change in tamoxifen metabolism (Osborne et al.,
1992), mutations in the oestrogen receptor (Graham et al.,
1990; Pakdel & Katzenellenbogen, 1992) or oestrogen recep-
tor splice variants (McGuire et al., 1991; Murphy & Dotzlaw,
1989; Scott et al., 1991).
To further examine resistance to tamoxifen in the presence
of oestrogen receptors, we have attempted transfection of
tamoxifen resistance into the tamoxifen sensitive MCF-7 cell
line. In view of the possibility that novel autocrine growth
pathways may lead to tamoxifen resistance, a mixture of
several cDNA libraries from hormone unresponsive cells was
used in the transfection. As stimulation of some cell types
with cytokines is known to induce expression ofcell adhesion
molecules and secreted growth factors, cDNA libraries from
such stimulated cells were used. Tamoxifen selection was
carried out in the presence of oestrogens to approximate as
closely as possible to the situation in which resistance arises
in vivo. Tamoxifen levels similar to those achieved in plasma
in vivo with conventional dosage regimens were used (Lien et
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al., 1989). We now report isolation of tamoxifen resistant
MCF-7 cells following cDNA transfection of such cDNA
libraries. One of the clones (clone 9) retains oestrogen recep-
tors and shows cross resistance to 4-hydroxytamoxifen as
well as to the new pure anti-oestrogen ICI 164,384. Clone 9 is
the first breast carcinoma line to show resistance to tamox-
ifen both in vitro and in vivo while continuing to express
oestrogen receptors, and provides an in vitro model with
which to investigate the mechanism of such resistance.
Materials and methods
Materials
acJP-dCTP and 3H-methylthymidine were from Amersham
plc, Amersham, UK. TGF-P, was from British Biotechnology
Ltd., Oxford, UK. 17-P-Oestradiol slow release pellets were
from Innovative Research of America, Toledo, Ohio, USA.
Routine laboratory chemicals were from Sigma or B.D.H.
All tissue culture media were from the ICRF Central Ser-
vices. Foetal calf serum was from J. Bio, Les Ulis, France.
BALBc NuNu mice were bred and housed at the ICRF Clare
Hall Laboratories, South Mimms, UK.
Methods
Transfection ofMCF-7 cells with cDNA libraries
MCF-7 cells (2 x 107) were detached by treatment with tryp-
sin, pelleted and resuspended in 1 ml of DMEM containing
20fig of the following cDNA libraries in pCDM8: U937
lymphoma; endotoxin, interleukin-1 and tumour necrosis
factor-t activated human umbilical vein endothelial cells and
proliferating (fibroblast growth factor stimulated) bovine
adrenal capillary endothelial cells. For each library, one half
(10pg) of the DNA was linearised by overnight incubation
with Sfil prior to transfection. Co-transfection with 10tig of
pSV2-gpt containing the E. coli xanthine-guanine phosphori-
bosyl transferase gene (XGPRT) (gpt resistance gene) was
carried out by electroporation with a capacitance of 25g.F as
follows (i) control electroporation at 300 V (no exogenous
DNA), (ii) gpt resistance plasmid alone at 300V and (iii)
cocktails with gpt resistance plasmid and the above libraries
at the following voltages 300, 330, 360 and 390. After electro-
poration cells were seeded into a 15 cm petri dish in DMEM/
10% FCS and left for 24 h to recover.
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Sequential selection oftransfectantsfor gpt and tamoxifen
resistance. gpt selection
After 24 h in DMEM/10% FCS, cells were subjected to
mycophenolic acid selection in the following medium:
DMEM/10% dialysed FCS supplemented with xanthine
(250 ig ml1'), hypoxanthine (15 igml-'), thymidine (10 ig
ml-'), mycophenolic acid (15jigml-') and aminopterin (2 jig
ml-') for 14 days (Mulligan & Berg, 1981). Then with the
same media lacking aminopterin and with the mycophenolic
acid concentration reduced to 10iLgml-' for a further 14
days. At this point selection medium was removed and cells
grown on for a further 10 days in DMEM/10% FCS by
which time distinct colonies of transfectants were clearly
visible. Typically each transfection gave rise to -104 colonies
(i.e. a transfection efficiency of 0.05%). All cells were dead in
the control (no DNA) transfection. Transfection with 300 V
was optimal.
Tamoxifen selection
On completion of mycophenolic acid selection, the clones
from transfected libraries were subjected to tamoxifen selec-
tion in situ as follows: DMEM/10% FCS supplemented with
tamoxifen (1 jiM) for 14 days. Culture medium was replaced
every 2 days. At this point the control gpt transfection
contained a few small colonies. By contrast the 300 V library
transfection contained ten rapidly growing colonies (i.e.
tamoxifen resistance to one in two million) and the 330-
390 V transfections a further ten colonies between them. All
20 colonies were removed by exposure to trypsin within
stainless steel cloning rings and cultured in the continued
presence of tamoxifen (1 jM) before freezing back. Clones 1,
3 and 9 showed the fastest growth in the presence of 1 jM
tamoxifen and were selected for further study. After a further
3 months culture in the presence of tamoxifen (1 jM) they
were phenotypically characterised.
Characterisation ofgrowth properties oftransfectant clones
relative to wild type MCF-7. 3H-methylthymidine uptake assay
Mitogenesis assays were performed in 96 well tissue culture
plates. MCF-7 wild type or transfectants were grown in
oestrogen free conditions for 2 weeks before being seeded at
3,000 cells/well in 10% DCC treated FCS, left 24 h and then
treated with 17-P-oestradiol (500 pM) with or without anti-
oestrogen in fresh PRF DMEM/10% DCC treated FCS.
17-,B-oestradiol (500 pM) and anti-oestrogens were present for
a further 4 days at which time cells were pulse labelled with
0.5 iLCi of 3H-methylthymidine per well for 4 h before being
removed by treatment with trypsin and harvested with an
automated 96 well harvester directly onto filter mats and
counted in a Pharmacia-Wallac flat bed betaplate scintillation
counter. All experiments were repeated at least once with
similar results.
Cell counting to determine growth curves
The indicated number of cells were seeded into six well tissue
culture plates in PRF DMEM/10% DCC treated FCS. At
appropriate times, cells were detached by exposure to trypsin
and counted in a Coulter counter. Cells were fed with fresh
PRF DMEM/10% DCC treated FCS, with or without inhib-
itors on days 3, 5 and 7.
Colonyformation in soft agar
Three thousand cells were suspended in 300 jl of 0.3%
'Difco' noble agar in PRF DMEM/10% DCC treated FCS
and layered over 0.3 ml of a 0.6% agar-medium basal layer
in 24 well tissue culture plates. Samples were then fed with
PRF DMEM/10% DCC treated FCS supplemented with
tamoxifen (0, 1, 5 or 10jM) and incubated at 37°C for 17
days. Half of the samples were also supplemented with 17-0-
oestradiol (1 nM). On day 17 the number of colonies >30-
40jLm in diameter was then counted by eye. The relative size
of the colonies was also noted. All points were triplicates.
Experiments were repeated twice.
DNA extraction and Southern blotting
MCF-7 or transfectants (2 x 107 cells) were lifted with tryp-
sin and pelleted. The pellet was washed with PBS (x 2) and
then lysed with 4 ml of the following buffer 0.1 M NaCl,
0.01 M Tris-HCl, 0.025M EDTA, pH 8 and 0.5% SDS.
Proteinase K was added to 100jigml' and the solution
incubated at 50°C overnight. RNase A (1 jig ml-') was
added, followed by a further incubation at 37°C for 1 h. The
DNA was then extracted sequentially with phenol, phenol/
chloroform (1:1) and then chloroform before dialysis against
three changes of 10 mM Tris-HCl, 1 mM EDTA, pH 8. Isolat-
ed DNA was stored at 4°C.
Samples of DNA were restricted with SpeI/HindIII (to
probe for the CMV promoter) with SacII/SpeI (to probe for
supF) and with HindIII/BglIl (to probe for gpt). DNA (10jg
per lane) was electrophoresed in 0.7% agarose gels and trans-
ferred to 'HyBond' nylon membranes by capillary blotting
using 0.4 M NaOH as convectant. Filters were prehybridised
overnight at 72°C in 10% dextran sulphate, 10 x Denhardts
solution (270 mM NaCl, 15 mM sodium phosphate, 1.5 mM
EDTA, pH 7), 2% SDS and salmon sperm DNA (400 jg
ml-'). Hybridisation was carried out overnight at 72°C under
the same conditions as for pre-hybridisation, but including
cDNA probes labelled by random priming. Filters were
washed to a stringency of 0.1 x SSC, 1% SDS at 55°C and
then exposed to preflashed film at -70°C. Probes were
removed from filters by treatment with 0.4M NaOH for
30 min at 45°C, followed by treatment with 0.2 M Tris-HCl,
0.1 x SSC, 0.1% SDS, pH 8 at 45°C for 30min.
Oestrogen and EGFreceptor assay
The oestrogen receptor number in oestrogen-depleted cells
was determined by the DCC ligand binding assay in accord
with EORTC guidelines (EORTC, 1980). Cytosolic fractions
were prepared as previously described (Leake et al., 1981)
from subconfluent cells. EGF receptors were measured by a
competitive binding assay on membrane fractions (Smith et
al., 1989).
Conditioning ofculture media by wild type MCF-7 and clone 9
transfectant
Subconfluent cells were washed (x 3) with DMEM and then
left for 48 h to condition DMEM. Media was collected and
dialysed against water (x 3) with tubing of molecular weight
cut-off 3.5 kDa. Protein was freeze dried, reconstituted with
x 10 PRF DMEM and water to give a solution in PRF
DMEM. 3H-methylthymidine assays were then performed as
described above in 2% DCC treated FCS.
Xenografts in BALBc NuNu mice
BALBc NuNu mice were ovariectomised and received two
subcutaneous implants. One a 60-day release pellet contain-
ing 1.5 mg 17-p-oestradiol and the other 107 MCF-7 cells.
The pellet was placed at the back of the neck and the cells in
the flank. Half of the mice then received twice weekly s.c.
injection of 100jig tamoxifen in 200jIl of sesame oil. The
controls received sesame oil alone. Tumour measurements
were performed twice weekly.
Results
Transfection ofMCF-7 cells and Southern analysis
In preliminary experiments a tamoxifen selection protocol
was developed such that of 2 x 107 wild type cells placed
under selection, none survived and we were unable to deter-1090 M. TOI et al.
mine the frequency of spontaneous resistance. MCF-7 can
give rise to spontaneously anti-oestrogen resistant lines (see
e.g. Nawata et al., 1981) but it appears that many more cells
have to be placed under selection. The selection protocol
used here involved replacing the culture media every other
day with fresh 10% FCS/DMEM containing 1 JAM tamoxifen.
After transfection of the cDNA libraries and mycophenolic
acid selection the gpt control and the gpt/library transfection
each gave rise to around 104 discrete colonies. These were
subjected directly to tamoxifen selection in situ. At 14 days
the gpt control showed only two remaining colonies that did
not appear to be proliferating. By contrast, the library trans-
fectants containing 20 rapidly growing colonies. Thus, 20
resistant clones were obtained from 104 transfectants,
whereas wild type MCF-7 failed to give rise to any resistant
clones from 2 x 107 cells. This argues strongly for resistance
to have arisen as a result of the transfection event. Of the
tamoxifen resistant transfectants, clones 1, 3 and in particular
9 were fast growing in the presence of 1 gM tamoxifen. These
three clones were chosen for further characterisation. Figure
1 shows Southern analysis of DNA from these cells probed
with (a) CMV promoter and (b) supF. Probing for the CMV
promoter (Figure la) gave a strong- positive in clone 9,
however, a weak band was also present in wild type cells,
suggesting that they may contain CMV promoter sequences.
The lane labelled T corresponds to a digest of DNA from a
transient transfection of HL60 cells with pCDM8 and P to a
digest of the plasmid pCDM8. In view of the weak signal for
CMV sequences in wild type MCF-7, we also probed for the
bacterial gene supF. Figure lb shows that supF is clearly
present in clones 3 and 9 but absent from wild type MCF-7.
We conclude that clones 3 and 9 are stable transfectants.
Probing for gpt showed this to be absent in wild type MCF-
7, but present in all transfectants (data not shown), consis-
tent with their growth under mycophenolic acid selection.
Effect ofthe anti-oestrogens tamoxifen, 4-hydroxytamoxifen
and ICI 164,384 on 3H-methylthymidine uptake andgrowth of
MCF-7 wild type and clone 9 cells
The effect of 17-,-oestradiol and of anti-oestrogens on 3H-
methylthymidine uptake and on growth of MCF-7 wild type
and clone 9 cells was examined in PRF DMEM/10% DCC
treated FCS after culture of the cells in this media for 2
weeks to deprive them of oestrogens. Figure 2 shows dose
response curves for the inhibition of 17-p-oestradiol (500 pM)
stimulated 3H-methylthymidine uptake by (a) tamoxifen, (b)
4-hydroxytamoxifen and (c) ICI 164,384. 3H-methylthymidine
uptake was measured by pulse labelling at the end of the
a
b
9 3 P WT TP
Figure 1 Southern analysis of transfectants. a, Probing for the
CMV promoter. Left to right: wild-type MCF-7, clone 9, clone 3,
clone 1, DNA from a pCDM8 transient transfection into HL60
cells (T) and a digest of plasmid CDM8 (P). b, Probing for the
supF gene. Left to right: clone 9, clone 3, digest of pCDM8, wild
type MCF-7, transient transfection of HL60 cells with pCDM8
containing the gene for CD31 (T) and finally a digest of plasmid
CDM8 (P).
experiment to avoid any effects of variation in growth rates
in the first few days of the experiment. Clone 9 was seen to
be markedly more resistant to the growth inhibitory effect of
tamoxifen and 4-hydroxytamoxifen than were wild type cells.
Substantial inhibition of wild type growth was seen in 10-8 M
4-hydroxytamoxifen whereas higher concentrations of 4-
hydroxytamoxifen (10-6 M) were required to see similar
inhibition in clone 9. Clone 9 is more resistant to ICI 164,384
than wild type cells but appears less so than it is to the other
two anti-oestrogens. Growth curves confirmed that the effects
on 3H-methylthymidine uptake reflect true effects on cell
growth. Thus, Figure 3a shows that wild type cells are
stimulated by 17-,-oestradiol and that this stimulation is
blocked by tamoxifen (1 JM), 4-hydroxytamoxifen (100 nM)
or ICI 164,384 (100nM). The observation that tamoxifen
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Figure 2 Anti-oestrogen inhibition of 17-p-oestradiol (500pM)
stimulated 3H-methylthymidine uptake by MCF-7 wild type (0)
and MCF-7 clone 9 (-) transfectant. a, tamoxifen, b, 4-hydroxy-
tamoxifen and c, ICI 164,384. For conditions see methods.
(ordinate: mean c.p.m. per well +s.d., n = 10 where error bars are
not shown they fell within the size of the symbol.)TRANSFECTION OF TAMOXIFEN RESISTANCE 1091
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Figure 4 Dose response of 3H-methylthymidine uptake by MCF-
7 wild type (0) and MCF-7 clone 9 transfectant (@) in response
to 17-p-oestradiol. Two week oestrogen depleted cells were seeded
at 3,000 cells/well and treated with 17-p-oestradiol for 4 days in
PRF DMEM/5% DCC treated FCS. Cells were pulse labelled for
4 h with 3H-methylthymidine before harvesting (mean, ±s.d.,
n= 10).
formed colonies in the presence of 5tLM tamoxifen (Figure
6c), a concentration of tamoxifen at which wild type cells
showed no growth (data not shown). Colony formation by
MCF-7 wild type cells was stimulated by 17-p-oestradiol; but
not that of clone 9 which grew equally fast in the absence of
oestrogens (Figure 5a). However, the growth of clone 9
became oestrogen responsive when antagonised by the pre-
,____ .____ ,____ ,____.____ ,___ sence of either 1 or 5 jAM tamoxifen (Figure 5a).
2 4 6 8 10 These findings raise the possibility that the resistance of
Day clone 9 to 1 and 5 fLM tamoxifen is due simply to its faster
growth rate or greater colony forming ability. This is not the
anti-oestrogens on growth curves for MCF-7 case, for, as shown in Figure Sb, after normalisation of the
-7 clone 9 transfectant. (0) control growth number of colonies, clone 9 is still markedly less inhibited by
)estradiol), (A) with 17-p-oestradiol (500 pM), 1 and 5 J.M tamoxifen. Further experiments examined colony
adiol and tamoxifen (1I M), (U) with 17-p- formation in the presence of 4-hydroxytamoxifen and ICI
Iroxytamoxifen (100 nM) and (A) with 17-p- 164,384 both on supplementation with 17-p-oestradiol (1 nM)
164,384 (100nM). Cells were oestrogen or in PRF DMEM/DCC treated FCS. In each case, clone 9
ing at day 1. Cells we re-fed with fresh was substantially more resistant than either wild type or
ni-oestrogen in PRF DMEM/10% DCC treat- clone 3 (data not shown). Resistance was particularly striking
5 and 7 (mean±Rs.d., n = 2). in the absence of 17-p-oestradiol. Colony formation by clone
9 in the absence of oestragens may be a component of the
tamoxifen resistant phenotype.
reduces proliferation below that in the PRF DMEM control
suggests that there remains residual oestrogen in the culture
medium. Figure 3b shows that oestrogen had no detectable
effect on the rate of growth of clone 9. By contrast, clone 9
continues to show substantial growth in the presence of all
three anti-oestrogens. The growth in the presence of ICI
164,384 is particularly interesting in view ofthe lower level of
resistance shown by clone 9 in the 3H-methylthymidine up-
take assay (Figure 2c). To confirm that clone 9 is less respon-
sive to oestrogen we examined 3H-methylthymidine uptake in
response to oestradiol. Figure 4 shows that the percentage
stimulation of clone 9 by oestradiol is less (+8%) than that
maximally seen with MCF-7 wild type cells (+25%). This
accords with the poor stimulation of clone 9 growth by
17-f-oestradiol (Figure 3b).
Colonyformation in soft agar
The growth of MCF-7 wild type and clone 9 cells in soft agar
was examined in PRF DMEM/10% DCC treated FCS in the
presence of 0, 1 and 5i4M tamoxifen (Figure Sa). Half of the
samples also received 17-p-oestradiol (1 nM). Differences were
apparent between the wild type and clone 9 cells. Not only
were there many more colonies ofclone 9 cells but the colony
size was larger relative to controls (Figure 6). Clone 9 also
Effect ofmedia conditioned by wild type MCF-7 and clone 9
on 3H-methylthymidine uptake by both cell lines
DMEM was conditioned by cultures of MCF-7 wild type
and clone 9 cells under identical conditions. These media
were then dialysed, freeze dried and reconstituted to give a
solution in PRF DMEM/2% DCC treated FCS. These media
were tested for their effects on 3H-methylthymidine uptake in
both MCF-7 wild type and clone 9 cells. Figure 7 shows that
medium conditioned by wild type MCF-7 was inhibitory to
both wild type MCF-7 and clone 9. This presumably reflects
the activity of inhibitory cytokines outweighing that of
stimulatory cytokines e.g. MCF-7 are known to produce and
to be inhibited by TGF-P, (Zugmaier et al., 1989; Knabbe et
al., 1987). In contrast medium conditioned by clone 9 stimu-
lated 3H-methylthymidine uptake in both cell types when
compared to PRF DMEM/2% DCC treated FCS controls.
We conclude that transfection has induced secretion of a
mitogen (or reduced secretion of an inhibitor) by the MCF-7
cells.
Oestrogen and EGF receptor expression
The data in Table I shows that there was a small decrease in
the oestrogen and a somewhat larger decrease in the EGF1092 M. TOI et al.
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Figure 5 Growth of MCF-7 wild type and transfectant clones 1, 3 and 9 in soft agar. Assays were carried out as described in
Methods either with or without 1 nM 17-p-oestradiol supplementation during the growth of the colonies. a, colony number; b,
Inhibition by anti-oestrogens (in the presence of I nM 17-p-oestradiol) normalised to the number of colonies formed by MCF-7
wild type cells. Wild type (0) and clone 9 (-).
receptors in those transfectants examined (including clone 9)
when compared to wild type cells. However, in each case
both receptors were clearly detectable.
Xenografts in BALBc NuNu mice
Neither wild type MCF-7 nor clone 9 cells form tumours
when injected s.c. (107 cells) into ovariectomised BALBc
NuNu mice that had not received a slow release oestrogen
implant. In contrast, when the mice also received an oes-
trogen implant, slow growing tumours formed. If the mice
also received tamoxifen, tumours from both wild type and
clone 9 between days 15 and 25 grew significantly faster than
those in control mice (Figure 8). However, beyond day 30 of
implantation marked differences became apparent. Tumours
from wild type cells ceased growing and subsequently started
to regress. By day 53 two tumours had become immeasurably
small and the analysis was terminated. In contrast, tumours
from clone 9 cells continued to grow up to day 47 (end of
experiment) at a rate that was indistinguishable from clone 9
tumours in mice that did not receive tamoxifen. We note that
the tumours formed by clone 9 cells were all significantly
smaller than those formed by wild type MCF-7. The reason
for this is not known.
Discussion
The tamoxifen resistant clone 9, isolated after cDNA trans-
fection, shows an in vitro phenotype similar to one of the
major types of clinical anti-oestrogen resistance, namely,
tamoxifen resistance in the presence of expressed oestrogen
receptors. Patients with recurrent disease and oestrogen
receptor positive tumours respond well to tamoxifen (approx-
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Figure 7 3H-Methylthymidine uptake in response to media con-
ditioned by MCF-7 wild type cells and clone 9 by cells of the
same lineage. Dialysed and freeze dried conditioned medium was
reconstituted in PRF DMEM/2% DCC treated FCS. Cells were
exposed to media for 48 h before harvesting (mean, ± s.e.m.,
n= 10). In each case the increase over 2% FBS seen with clone 9
conditioned media and decrease seen with wild type conditioned
C media was highly significant (P<0.001). The experiment was
repeated three times with similar results.
Table I Expression of oestrogen and EGF receptors in wild type and
transfected MCF-7 cells
Figure 6 Growth of MCF-7 wild type a, and clone 9 transfec-
tant b, in soft agar in the presence of 1 gM tamoxifen. Growth of
clone 9 transfectant in the presence of 5 iM tamoxifen c. In each
case 1 nM 17-f-oestradiol was added to PRF DMEM/10% DCC
treated FCS.
imately 50-60% response rate). While the majority relapse
within 2 years, if treated with a second anti-hormonal
therapy, approximately 50% may respond again (Smith et
al., 1983). Oestrogen receptors are detectable in patients
relapsing on tamoxifen, but not all of these respond to
second line therapy (Leake et al., 1981; Taylor et al., 1982). It
is this latter group of patients with oestrogen receptor
positive tumours failing tamoxifen after an initial response,
and not responding to further endocrine manipulation, who
present a major clinical problem. Clone 9 has a phenotype
that makes it a suitable model with which to investigate the
mechanism(s) of such resistance. The parent MCF-7 cells
that were transfected are hormone responsive and anti-
oestrogen sensitive. Clone 9 responds to anti-oestrogens but
requires higher doses for inhibition than do wild type cells.
Clone 9 also grows in vitro but not in vivo in the absence of
oestrogen. The latter apparent discrepancy indicates that
while oestrogen is not needed for growth of clone 9 it is
needed for successful tumour formation. It is possible that
oestrogen stimulates release of, for example, an angiogenic
factor or protease (e.g. stromolysin) which is essential for
Cell line Oestrogen receptor EGF receptor
fmolmg-' protein fmolmg-' protein
Wild type 79 5.8
Clone 1 36 0.1
Clone 3 52 not done
Clone 9 30 1.4
Receptors were assayed by a competitive ligand binding assay. Cells
werecultured in PRFDMEM/10% DCC treated FCS for2 weeks prior
to oestrogen receptor assay.
tumour formation but that has no effect on the in vitro
growth rate of the cells.
Oestrogen receptors were detectable in clone 9 by ligand
binding (Table I) and we conclude that a major deficiency in
hormone binding does not account for resistance. Although
oestrogen receptors were lower in clone 9, the level of expres-
sion is well within the range associated with hormone respon-
siveness (Bezwoda et al., 1991). Further, resistance to three
anti-oestrogens, including ICI 164,384 which is thought to
exert its anti-oestrogenic effect by a different mechanism to
that of tamoxifen (Dauvois et al., 1992), is consistent with
resistance not arising from mutation in the oestrogen recep-
tor.
Inhibitory growth factors are an important pathway by
which tamoxifen is thought to mediate its effect (Knabbe et
al., 1987; Colletta et al., 1990). The secretion of active TGF-
PI, an inhibitor of breast carcinoma cells in culture (Zug-
maier et al., 1989; Knabbe et al., 1987; Toi et al., 1992) is
induced by tamoxifen (Knabbe et al., 1987) and loss of
TGF-P13 receptors could produce tamoxifen resistance. How-
ever, both wild type MCF-7 and clone 9 were similarly
inhibited by TGF-P1 (data not shown) and this fails to
explain the resistance that we have observed here.
It has been shown that the expression of several growth
factors and growth factor receptors is markedly changed in
anti-oestrogen resistant tumours, for example, we have
T1094 M. TOI et al.
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200 1l of sesame oil. Control (0), tamoxifen tr(
±s.e.m., wild type n = 10, clone 9, n = 5). The
repeated twice with similar results.
previously shown high EGF receptor and c-
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1988, 1989; Wright et al., 1992; Sainsbury et
al., 1990). There is also an inverse relations}
rogen and EGF receptor expression in breast cancer and a
switch to an EGF receptor positive phenotype (up-regulation
of EGF receptor) may be associated with hormone resis-
tance. In clone 9, however, the EGF receptor level was lower
than in the parental cells, as was the case in the other less
tamoxifen resistant clones for which EGF receptor expression
was determined.
The experiments in which medium was conditioned by wild
type MCF-7 or clone 9 and then reconstituted in PRF
DMEM/2% DCC treated FCS and administered back to
quiescent cells suggest that an enhanced autocrine loop could
account for the hormone independent growth. Medium con-
ditioned by clone 9 cells stimulated wild-type and clone 9,
whereas medium from MCF-7 wild-type cells was inhibitory
to both types (Figure 7). Candidate growth factors could be
TGF-J, insulin like growth factors, or fibroblast like growth
factors all of which have been reported to stimulate growth
of breast carcinoma cells.
The degree of resistance demonstrated by clone 9 varied
depending on the endpoint selected, but in all assays was
significantly more resistant than wild-type MCF-7. Thus, in
the inhibition of 3H-methylthymidine uptake ICm differs by a
factor of ten between the two cell lines. Inhibition at 1 LM
a tamoxifen, the plasma level found with conventional dosing
(Lien et al., 1989), was 20% for clone 9 vs 100% for wild
type MCF-7 i.e. a 5-fold difference. When growth curves
were determined by cell counting, inhibition at day 9 of
oestrogen stimulated growth was complete with wild type
cells but clone 9 was unaffected (Figure 3).
Oestrogen hypersensitivity could also account for some of
the featues of clone 9, with minute amounts residual in DCC
treated FCS or carried over in cells causing apparent hor-
mone 'independent' growth. Dose response curves to oestra-
diol showed this was not the case, however, and that clone 9
actually has a reduced response to 17-p-oestradiol (Figure 4),
a result in accord with the growth curve shown in Figure 3b.
Tamoxifen stimulation is another reported mechanism of
tamoxifen resistance in vivo, but in vitro the growth curves
clearly show no such effect in clone 9. It is possible that
50 60 downstream pathways normally regulated by oestrogen have
become constitutively activated and it would be of interest to
analyse oestrogen regulated genes such as pS2, cathepsin D,
b and the oestrogen receptor in this transfectant. The results
with the pure anti-oestrogen suggest that some patients relap-
sing after tamoxifen therapy may not benefit from a second
hormonal therapy. Alterations in tamoxifen metabolism or
poor tamoxifen uptake are other mechanisms of resistance
(Osborne et al., 1991, 1992; Weibe et al., 1992). However,
they cannot account for hormone independent growth in
agar, and the fact that the clone 9 cell line is resistant to an
entirely different structural class of anti-oestrogen.
Previously, several other tamoxifen resistant or hormone
independent cell lines have been isolated by exposure to
selecting drugs or by transfection of oncogenes. Their pheno-
types are summarised in Table II. Clinical studies have cor-
related high level EGF receptor expression with hormone
independent growth of human breast cancer (Nicholson et
al., 1988, 1989). However, clone 9 MCF-7 cells show hor-
40 50 mone independent growth but a decrease in expression of
EGF receptors relative to the hormone dependent wild-type
cells. Similarly spontaneously tamoxifen resistant lines such
ne 9 transfectant as R-27 and LY2 have EGF receptor numbers per cell that
ed and received a fall well within the range of wild type MCF-7. To examine
7amoxifen treated whether overexpression of the EGF receptor leads to hor-
)fig tamoxifen in mone independent growth, the EGF receptor was transfected
eated (0) (mean, into the hormone dependent human breast carcinoma line
e experiment was ZR75. The results are controversial. Thus, while one study
(Valverius et al., 1990) claims that high level expression of
the receptor failed to alter hormone dependency or tamoxifen
sensitivity, a second study (van Agthoven et al., 1992) has
disagreed. We conclude that in vivo EGF receptor expression
erbB-2 expression plays a complex and possibly paracrine role in the evolution
(Nicholson et al., of hormone independent growth.
t al., 1987; Toi et IGF-II which is known to be a growth factor for breast
hip between oest- carcinoma cells (Osborne et al., 1989) has been transfected
Table II Tamoxifen resistant and/or hormone independent cell lines
isolated from MCF-7 cells
In vitro Soft agar Xenograft
Cell line H.D. T.S. H.D. T.S. H.D. T.S.
MCF-7 WTa + + + + + +
Group A
R-27b - - N.D. N.D. + +
BSK-2 and 3c _ + N.D. N.D. - N.D.
LY-2d + - N.D. N.D. Not
tumourigenic
Group B
M IIIe - + - + _ +
MCF-TAMf + + N.D. N.D. E2 and TAM
dependent
MCF-7 ADR9 - - N.D. N.D. - N.D.
Group C
Clone 9 - - - - +
Abbreviations: H.D., hormone dependent; T.S. tamoxifen sensitive;
N.D., notdetermined. aSouleetal.(1973);bNawataetal.(1981);cClarke
etal.(1989);dBronzert etal.(1985);eClarkeetal.(1990); fGottardisetal.
(1988); 9M. Toi, A.L. Harris & R. Bicknell - unpublished data.
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into MCF-7 cells. Transfectants exhibited a considerably
reduced response to oestrogen but inhibition by tamoxifen
was unchanged (Daly et al., 1991). Transfection of v-rasH
into MCF-7 cells was reported to confer hormone indepen-
dent growth (Kasid et al., 1985). However, this result has
been challenged by others who followed a similar strategy
but were unable to obtain hormone independent clones
(Sommers et al., 1990; Sukumar et al., 1988). It can be seen
from Table II that none of the cell lines have phenotypes
comparable to clone 9 which shows resistance to 4-hydroxy-
tamoxifen, ICI 164,384, down-regulation of EGF receptors,
hormone independent growth in soft agar and tamoxifen
resistance in vivo.
Although clone 9 was isolated after DNA transfection, this
does not prove that the resistance is due to transfection.
However, there are clearly vector sequences present based on
detection of the bacterial gene supF in clone 9 but not in wild
type MCF-7 (Figure lb). We are currently attempting to
identify a transfected gene that may give rise to tamoxifen
resistance in clone 9 cells. The involvement of such a gene in
breast cancer tamoxifen resistance would then need to be
examined.
Understanding the mechanisms of hormone resistance is of
increasing importance in view of the widespread use of
tamoxifen in adjuvant therapy (Collins et al., 1992). A know-
ledge of the mechanism will allow the development of new
therapeutic approaches for this particular subgroup of
patients resistant to hormone therapy i.e. those with oest-
rogen receptor positive tumours that are unresponsive to
aromatase inhibitors and to second line hormone therapy.
The authors thank Dr Colin Potter, Nuffield Department of Medi-
cine for access to an automated 96 well harvester and flat bed
betaplate scintillation counter and Dr David Simmons, ICRF, Insti-
tute of Molecular Medicine for supplying cDNA libraries.
Abbreviations DMEM, Dulbecco's modified Eagle's medium (supple-
mented with 105 units of streptomycin and 110 mg 1-1 of penicillin);
FCS, foetal calf serum; DCC, dextran coated charcoal; PRF, phenol
red free; CMV, cytomegalovirus; EGF, epidermal growth factor;
TGF-pl, transforming growth factor-p1.
References
VAN AGTHOVEN, T., VAN AGTHOVEN, T.L.A., PORTENGEN, H., FOE-
KENS, J.A. & DORSSERS, C.J. (1992). Ectopic expression of
epidermal growth factor receptors induces hormone independence
in ZR-75-1 human breast cancer cells. Cancer Res., 52, 5082-
5088.
BEZWODA, W.R., ESSER, J.D., DANSEY, R., KESSEL, I., RAD, M.M. &
LANGE, M. (1991). The value ofestrogen and progesterone recep-
tor determinations in advanced breast cancer. Cancer, 68, 867-
872.
BRONZERT, D.A., GREENE, G.L. & LIPPMAN, M.E. (1985). Selection
and characterization of a breast cancer cell line resistant to the
antioestrogen LY117018. Endocrinology, 117, 1409-1417.
CLARKE, R., BRUNNER, N., KATZENELLENBOGEN, B., THOMPSON,
E.W., NORMAN, M.J., KOPPI, C., PAIK, S., LIPPMAN, M.E. &
DICKSON, R.B. (1989). Progression of human breast cancer cells
from hormone-dependent to hormone-independent growth both
in vitro and in vivo. Proc. Natl Acad. Sci. USA, 86, 3649-3653.
CLARKE, R., DICKSON, R.B. & BRUNNER, N. (1990). The process of
malignant progression in human breast cancer. Ann. Oncol., 1,
401-407.
COLLETTA, A.A., WAKEFIELD, L.M. & HOWELL, F.V. (1990). Anti-
oestrogens induce the secretion of active transforming growth
factor beta 1 from human fetal fibroblasts. Br. J. Cancer, 62,
405-409.
COLLINS, R., GRAY, R., PETO, R. & EARLY BREAST CANCER
TRIALIST'S COLLABORATIVE GROUP (1992). Systemic treatment
of early breast cancer by hormonal, cytotoxic or immune therapy.
Lancet, 339, 1-15 and 71-85.
CULLEN, K.J., LIPPMAN, M.E., CHOW, D., HILL, S., ROSEN, N. &
ZWIEBEL, J.A. (1992). Insulin-like growth factor-I1 overexpression
in MCF-7 cells induces phenotypic changes associated with
malignant progression. Molec. Endocrin., 6, 91-100.
DALY, R.J., HARRIS, W.H., WANG, D.Y. & DARBRE, P.D. (1991).
Autocrine production of insulin like growth factor II using an
inducible expression system results in reduced oestrogen sen-
sitivity of MCF-7 human breast cancer cells. Cell Growth Differ.,
2, 457-464.
DAUVOIS, S., DANIELIAN, P.S., WHITE, R. & PARKER, M.G. (1992).
Antiestrogen ICI 164,384 reduces cellular estrogen receptor con-
tent by increasing its turnovers. Proc. Natl Acad. Sci. USA, 89,
4037-4041.
EORTIC BREAST COOPERATIVE GROUP (1980). Revision of the
standards for the assessment of hormone receptors in human
breast cancer. Eur. J. Cancer, 16, 1313-1315.
GOTTARDIS, M.M. & JORDON, V.C. (1988). Development of tamoxi-
fen-stimulated growth of MCF-7 tumours in athymic mice after
long-term antioestrogen administration. Cancer Res., 48, 5183-
5187.
GRAHAM, M.L., KRETT, N.L., MILLER, L.A., LESLIE, K.K., GOR-
DON, F.D., WOOD, W.M., WEI, L.L. & HORWITZ, K.B. (1990).
T47D,0 cells, genetically unstable and containing oestrogen recep-
tor mutations, are a model for the progression of breast cancers
to hormone resistance. Cancer Res., 50, 6208-6217.
HARRIS, A.L., CANTWELL, B.M.J., CARMICHAEL, J., DAWES, P.,
ROBINSON, A., FARNDON, J. & WILSON, R. (1989). Phase II
study of low dose aminoglutethimide 250 mg per day plus hydro-
cortisone in advanced post menopausal breast cancer. Eur. J.
Cancer Clin. Oncol., 27, 1108-1111.
HARRIS, A.L., POWLES, T.J., SMITH, I.E., COOMBES, R.C., FORD,
H.T., GAZET, J.-C., HARMER, C.L., MORGAN, M.W., WHITE, H.,
PARSONS, C.A. & McKINNA, J.A. (1983). Aminoglutethimide for
the treatment of advanced postmenopausal breast cancer. Eur. J.
Cancer, 19, 11-17.
JOHNSTON, S.R.D., DOWSETT, M. & SMITH, I.E. (1992). Towards a
molecular basis for tamoxifen resistance in breast cancer. Ann.
Oncol., 3, 503-511.
KASID, A., LIPPMAN, M.E., PAPAGEORGE, A.G., LOWY, D.R. & GEL-
MANN, E.P. (1985). Transfection of v-rasH into MCF-7 human
breast cancer cells by-passes dependence on oestrogen for
tumourigenicity. Science, 228, 725-728.
KNABBE, C., LIPPMAN, M.E., WAKEFIELD, L.M., FLANDERS, K.C.,
KASID, A., DERYNCK, R. & DICKSON, R.B. (1987). Evidence that
transforming growth factor-P is a hormonally regulated negative
growth factor in human breast cancer cells. Cell, 48, 417-428.
LEAKE, R.E., LAING, L., CALMAN, K.C., MACBETH, F.R., CRAW-
FORD, D. & SMITH, D.C. (1981). Oestrogen-receptor status and
endocrine therapy of breast cancers: response rates and status
stability. Br. J. Cancer, 43, 59-66.
LIEN, E.A., SOLHEIM, E., LEA, O.A., LUNDGREN, S., KVINNSLAND,
S. & UELAND, P.M. (1989). Distribution of 4-hydroxy-N-des-
methyltamoxifen and other tamoxifen metabolites in human bio-
logical fluids during tamoxifen treatment. Cancer Res., 49, 2175-
2183.
MANNI, A. (1989). Endocrine therapy of metastatic breast cancer. J.
Endocrinol. Invest., 12, 357-372.
McGUIRE, W.L., CHAMNESS, G.C. & FUGUA, S.A.W. (1991). Oest-
rogen receptor variants in clinical breast cancer. Mol. Endocrinol.,
5, 1571-1577.
MULLIGAN, R.C. & BERG, P. (1981). Selection for animal cells that
express the E. coli gene encoding for xanthine-guanine phos-
phoribosyl transferase. Proc. Natl Acad. Sci. USA, 78, 2072-
2076.
MURPHY, L.C. & DOTZLAW, H. (1989). Variant oestrogen receptor
mRNA species detected in human breast cancer biopsy samples.
Mol. Endocrinol., 3, 687-693.
NAWATA, H., BRONZERT, D.A. & LIPPMAN, M.E. (1981). Isolation
and characterization of a tamoxifen-resistant cell line derived
from MCF-7 human breast cancer cells. J. Biol. Chem., 256,
5016-5021.
NICHOLSON, S., HALCROW, P., SAINSBURY, J.R.C., ANGUS, B.,
CHAMBERS, P., FARNDON, J.R. & HARRIS, A.L. (1988). Epider-
mal growth factor receptor status associated with failure of
primary endocrine therapy in elderly postmenopausal patients
with breast cancer. Br. J. Cancer, 58, 810-814.1096 M. TOI et al.
NICHOLSON, S., SAINSBURY, J.R.C., HALCROW, P., CHAMBERS, P.,
FARNDON, J.R. & HARRIS, A.L. (1989). Epidermal growth factor
receptor expression is associated with lack of response to endo-
crine therapy in patients with recurrent breast cancer. Lancet, i,
182-185.
OSBORNE, C.K., CORONADO, E.B., KITTEN, L.J., ARTEGA, C.I.,
FUGUA, S.A.W., RAMASHARMA, K., MARSHALL, M. & LI, C.H.
(1989). Insulin like growth factor II: a potent autocrine/paracrine
growth factor for human breast cancer acting via the IGF-1
receptor. Mol. Endocrinol., 3, 1701-1709.
OSBORNE, C.K., CORONADO, E. & WIEBE, V.J. (1991). Acquired
tamoxifen resistance: correlation with reduced tumor levels of
tamoxifen and isomerization of trans-4-hydroxytamoxifen. J.
Natl Cancer Inst., 83, 1477-1482.
OSBORNE, C.K., CORONADO, E. & WIEBE, V.J. (1992). Acquired
tamoxifen resistance in breast cancer correlates with reduced
tumor accumulation of tamoxifen and trans-4-hydroxytamoxifen.
J. Clin. Oncol., 10, 304-310.
PAKDEL, F. & KATZENELLENBOGEN, B.S. (1992). Human estrogen
receptor mutants with altered estrogen and antiestrogen ligand
discrimination. J. Biol. Chem., 267, 3429-3437.
SAINSBURY, J.R.C., NEEDHAM, G.K., MALCOLM., A., FARNDON,
J.R. & HARRIS, A.L. (1987). Epidermal growth factor receptor
status as predictor of early recurrence of and death from breast
cancer. Lancet, i, 1398-1402.
SCOTT, G.K., KUSHNER, P., VIGNE, J.-L. & BENZ, C.C. (1991). Trun-
cated forms of DNA-binding oestrogen receptors in human
breast cancer. J. Clin. Invest., 88, 700-706.
SMITH, I.E., HARRIS, A.L., MORGAN, M., FORD, H.T., GAZET, J.-C.,
HARMER, C.L., WHITE, H., PARSONS, C.A., VILLARDO, A.,
WALSH, G. & MCKINNA, J.A. (1983). Tamoxifen versus amino-
glutethimide in the treatment of advanced breast carcinoma: a
control randomised cross-over trial. B.M.J., 283, 1432-1434.
SMITH, K., FENNELLY, J.A., NEAL, D.E., HALL, R.R. & HARRIS, A.L.
(1989). Characterization and quantitation of the epidermal
growth factor receptor in invasive and superficial bladder
tumours. Cancer Res., 49, 5810-5815.
SOMMERS, C.L., PAPAGEORGE, A., WILDING, G. & GELMANN, E.P.
(1990). Growth properties and tumourigenesis of MCF-7 cells
transfected with isogenic mutants of rasH. Cancer Res., 50,
67-71.
SOULE, H.D., VAZQUEZ, J., LONG, A., ALBERT, S. & BRENNAN, M.
(1973). A human cell line from a pleural effusion derived from a
breast carcinoma. J. Natl Cancer Inst., 51, 1409-1416.
SUKUMAR, S., CARNEY, W.P. & BARBACID, M. (1988). Independent
molecular pathways in initiation and loss of hormone respon-
siveness of breast carcinomas. Science, 240, 524-526.
TAYLOR, R.E., POWLES, T.J. & HUMPHREYS, J. (1982). Effects of
endocrine therapy on steroid-receptor content of breast cancer.
Br. J. Cancer, 45, 80-85.
TOI, M., BICKNELL, R. & HARRIS, A.L. (1992). Inhibition of colon
and breast carcinoma cell growth by interleukin-4. Cancer Res.,
52, 275-279.
TOI, M., NAKAMURA, T., MUKAIDA, H., WADA, T., OSAKI, A.,
YAMADA, H., TOGE, T., NIIMOTO, M. & HATTORI, T. (1990).
Relationship between epidermal growth factor receptor status
and various prognostic factors in human breast cancer. Cancer,
65, 1980-1984.
VALVERIUS, E.M., VELU, T., SHANKAR, V., CIARDIELLO, F., KIM,
N. & SALOMON, D.S. (1990). Over-expression of the epidermal
growth factor receptor in human breast cancer cells fails to
induce an oestrogen independent phenotype. Int. J. Cancer, 46,
712-718.
WIEBE, V.J., OSBORNE, C.K., McGUIRE, W.L. & DEGREGORIO, M.W.
(1992). Identification of estrogenic tamoxifen metabolite(s) in
tamoxifen-resistant human breast tumors. J. Clin. Oncol., 10,
990-994.
WRIGHT, C., NICHOLSON, S., ANGUS, B., SAINSBURY, J.R.C., FARN-
DON, J., CAIRNS, J., HARRIS, A.L. & HORNE, C.H.W. (1992).
Relationship between c-erbB-2 protein product expression and
response to endocrine therapy in advanced breast cancer. Br. J.
Cancer, 65, 118-121.
ZUGMAIER, G., ENNIS, B.W., DIESCHAUER, B., KATZ, D., KNABBE,
C., WILDING, G., DALY, P., LIPPMAN, M.E. & DICKSON, R.B.
(1989). Transforming growth factors type P1 and P2 are equipo-
tent growth inhibitors of human breast cancer cell lines. J. Cell.
Physiol., 141, 353-361.